Scientific Programme - 11th European Multidisciplinary Congress on Urological Cancers (EMUC19)

Industry Session

View programme as: Grid view List view
Print: Print
Personal Planner

06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00

Foyer
Room 0.94 - 0.95
Auditorium
Room 0.96 - 0.97
Hall G1
Hall F2
Hall G2
Hall K1
Room 0.12

1. 06:00
2. 07:00
3. 08:00
4. 09:00
5. 10:00
6. 11:00
7. 12:00
8. 13:00
9. 14:00
10. 15:00
11. 16:00
12. 17:00
13. 18:00
14. 19:00
15. 20:00
16. 21:00
Auditorium
1. Plenary Session 07 - New trials update
  
  New trials update Plenary Session 07
  
  08:00 - 09:45
  New trials update
  
  Plenary Session 07
  
  Sat 16 November
  08:00 - 09:45
  
  Location:
  
  Auditorium
  
  Chairs:
  
  C. Salembier, Brussels (BE)
  A. Bamias, Athens (GR)
  T. Maurer, Hamburg (DE)
  
  08:00 - 08:15
  
  The SPCG4 study
  
  Speaker :
  
  P. Stattin, Uppsala (SE)
  
  Webcast
  
  Discussant :
  
  L.H. Klotz, Toronto (CA)
  
  Webcast
  
  08:15 - 08:30
  
  The ARAMIS trial
  
  Speaker :
  
  K. Fizazi, Villejuif (FR)
  
  Webcast
  
  Discussant :
  
  M. De Santis, Berlin (DE)
  
  Webcast
  
  08:30 - 08:45
  
  KEYNOTE 057
  
  Speaker :
  
  A.V. Balar, ()
  
  Webcast
  
  Discussant :
  
  A.M. Kamat, Houston (US)
  
  Webcast
  
  08:45 - 09:00
  
  Metastatic RCC: First line treatment
  
  Speaker :
  
  M. Schmidinger, Vienna (AT)
  
  Webcast
  
  Discussant :
  
  M-O. Grimm, Jena (DE)
  
  09:00 - 09:15
  
  Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial
  
  Speaker :
  
  A-G. Martin, ()
  
  Webcast
  
  Discussant :
  
  P. Hoskin, Northwood (GB)
  
  Webcast
  
  09:15 - 09:45
  
  Discussion
2. Welcome and introduction
  
  Welcome and introduction
  
  08:30 - 08:40
  Welcome and introduction
  
  Fri 15 November
  08:30 - 08:40
  
  Location:
  
  Auditorium
  
  Chairs:
  
  L. Albiges, Villejuif (FR)
  P. Hoskin, Northwood (GB)
  H.P.A.M. Van Poppel, Leuven (BE)
3. Plenary Session 15 - Announcement 3 best unmoderated posters
  
  Announcement 3 best unmoderated posters Plenary Session 15
  
  08:30 - 08:45
  Announcement 3 best unmoderated posters
  
  Plenary Session 15
  
  Sun 17 November
  08:30 - 08:45
  
  Location:
  
  Auditorium
  
  Chairs:
  
  P. Bono, Helsinki (FI)
  B. De Bari, Besancon (FR)
  R.J.A. Van Moorselaar, Amsterdam (NL)
4. Early detection of prostate cancer 40 years later. The 40th birthday of PSA
  
  •
  
  Early detection of prostate cancer 40 years later. The 40th birthday of PSA
  
  08:40 - 10:30
  Early detection of prostate cancer 40 years later. The 40th birthday of PSA
  
  Fri 15 November
  08:40 - 10:30
  
  Location:
  
  Auditorium
  
  Chairs:
  
  T. Wiegel, Ulm (DE)
  R. Oyen, Leuven (BE)
  E. Compérat, Paris (FR)
  C.H. Bangma, Rotterdam (NL)
  
  08:40 - 08:45
  
  PSA screening has to come back
  
  H.P.A.M. Van Poppel, Leuven (BE)
  
  Webcast
  
  08:45 - 08:55
  
  The story of PSA
  
  M.J. Roobol, Rotterdam (NL)
  
  Webcast
  
  08:55 - 09:05
  
  Early detection in prostate cancer in 2019
  
  P. Albers, Düsseldorf (DE)
  
  Webcast
  
  09:05 - 09:15
  
  Prostate cancer screening by MRI: Will it ever happen?
  
  H. Thoeny, Bern (CH)
  
  Webcast
  
  09:15 - 09:25
  
  Prostate cancer morphology: Major changes with clinical significance in the last 40 years
  
  R. Montironi, Ancona (IT)
  
  Webcast
  
  09:25 - 09:40
  
  Discussion
  
  09:40 - 09:50
  
  Biomarkers for early detection: Real game changers?
  
  G. Jenster, Rotterdam (NL)
  
  Webcast
  
  09:50 - 10:00
  
  Medical application of prostate cancer genomics
  
  M.A. Rubin, Berne (CH)
  
  Webcast
  
  10:00 - 10:30
  
  Discussion
5. Plenary Session 16
  
  • Pathology in active surveillance
  
  Pathology in active surveillance: Update and controversies Plenary Session 16
  
  08:45 - 09:15
  Pathology in active surveillance: Update and controversies
  
  Plenary Session 16
  
  Sun 17 November
  08:45 - 09:15
  
  Location:
  
  Auditorium
  
  Chair:
  
  R. Montironi, Ancona (IT)
  
  Discussant:
  
  A. Briganti, Milan (IT)
  
  08:45 - 09:05
  
  Pathology in active surveillance
  
  J. Epstein, Baltimore (US)
6. Debate - Treatment of metastatic prostate cancer
  
  Treatment of metastatic prostate cancer Debate
  
  09:15 - 10:35
  Treatment of metastatic prostate cancer
  
  Debate
  
  Sun 17 November
  09:15 - 10:35
  
  Location:
  
  Auditorium
  
  Chairs:
  
  P. Ost, Ghent (BE)
  S. Joniau, Leuven (BE)
  S. Gillessen Sommer, Manchester (GB)
  
  09:15 - 10:00
  
  Best treatment in de novo metastatic disease
  
  09:15 - 09:25
  
  Docetaxel
  
  S. Bracarda, Terni (IT)
  
  09:25 - 09:35
  
  Abiraterone
  
  P. Cornford, Liverpool (GB)
  
  09:35 - 09:45
  
  When to add local treatment
  
  R. Sanchez-Salas, Paris (FR)
  
  09:45 - 10:00
  
  Discussion
  
  10:00 - 10:35
  
  Oligometastatic recurrence - Imaging guided therapy
  
  10:00 - 10:10
  
  Yes
  
  G. De Meerleer, Leuven (BE)
  
  10:10 - 10:20
  
  No
  
  N. Mottet, Saint-Étienne (FR)
  
  10:20 - 10:35
  
  Discussion
7. Plenary Session 08 - Announcement 3 best unmoderated posters
  
  Announcement 3 best unmoderated posters Plenary Session 08
  
  09:45 - 10:00
  Announcement 3 best unmoderated posters
  
  Plenary Session 08
  
  Sat 16 November
  09:45 - 10:00
  
  Location:
  
  Auditorium
  
  Chairs:
  
  L. Albiges, Villejuif (FR)
  V. Fonteyne, Ghent (BE)
  S. Shariat, Vienna (AT)
8. Multidisciplinary case discussion - Residual disease after chemotherapy in testicular cancer
  
  Residual disease after chemotherapy in testicular cancer Multidisciplinary case discussion
  
  10:30 - 11:00
  Residual disease after chemotherapy in testicular cancer
  
  Multidisciplinary case discussion
  
  Sat 16 November
  10:30 - 11:00
  
  Location:
  
  Auditorium
  
  Case presenter:
  
  C. Oing, Hamburg (DE)
  
  Discussants:
  
  A. Heidenreich, Cologne (DE)
  J. Oldenburg, Lørenskog (NO)
  F. Giammarile, ()
  G. De Meerleer, Leuven (BE)
  L. Rocher, Paris (FR)
9. EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)
  
  EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)
  
  10:35 - 10:50
  EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)
  
  Sun 17 November
  10:35 - 10:50
  
  Location:
  
  Auditorium
  
  Chair:
  
  H.P.A.M. Van Poppel, Leuven (BE)
  
  10:35 - 10:50
  
  EU Joint Action (Innovative Partnership for Action Against Cancer IPAAC)
  
  T. Albreht, Ljubljana (SI)
10. Plenary Session 19 - Take home messages
  
  Take home messages Plenary Session 19
  
  10:50 - 11:40
  Take home messages
  
  Plenary Session 19
  
  Sun 17 November
  10:50 - 11:40
  
  Location:
  
  Auditorium
  
  10:50 - 11:40
  
  Take home messages
  
  10:50 - 11:00
  
  Take home message
  
  R. Montironi, Ancona (IT)
  
  11:00 - 11:10
  
  Take home message
  
  C. Salembier, Brussels (BE)
  
  11:10 - 11:20
  
  Take home message
  
  A. Briganti, Milan (IT)
  
  11:20 - 11:30
  
  Take home message
  
  R. Oyen, Leuven (BE)
  
  11:30 - 11:40
  
  Take home message
  
  A. Bamias, Athens (GR)
11. Multidisciplinary case discussion - Prostate cancer: From active surveillance to active treatment
  
  Prostate cancer: From active surveillance to active treatment Multidisciplinary case discussion
  
  11:00 - 12:00
  Prostate cancer: From active surveillance to active treatment
  
  Multidisciplinary case discussion
  
  Fri 15 November
  11:00 - 12:00
  
  Location:
  
  Auditorium
  
  Chairs:
  
  B. De Bari, Besancon (FR)
  G.N. Thalmann, Bern (CH)
  
  11:00 - 12:00
  
  Multidisciplinary case discussion From active surveillance to active treatment
  
  Case presenter :
  
  G. Ploussard, Toulouse (FR)
  
  Webcast
  
  Discussants :
  
  F. Montorsi, Milan (IT)
  
  T. Gevaert, Kluisbergen (BE)
  
  A. Bossi, Villejuif (FR)
  
  R. Renard-Penna, Paris (FR)
  
  L.H. Klotz, Toronto (CA)
12. Plenary Session 10 - Late breaking news session
  
  Late breaking news session Plenary Session 10
  
  11:00 - 11:25
  Late breaking news session
  
  Plenary Session 10
  
  Sat 16 November
  11:00 - 11:25
  
  Location:
  
  Auditorium
  
  Chairs:
  
  L. Albiges, Villejuif (FR)
  E. Xylinas, Paris (FR)
  
  11:00 - 11:11
  
  Update of the IGCCCG classification
  
  S. Gillessen Sommer, Manchester (GB)
  
  Webcast
  
  P162
  
  Timing of Radiotherapy (RT) after Radical Prostatectomy (RP): First results from RADICALS RT randomised controlled trial [NCT00541047]
  
  By: Parker C. ¹ , Clarke N.W. ² , Cook A. ³ , Kynaston H. ⁴ , Petersen P.M. ⁵ , Cross W. ⁶ , Persad R. ⁷ , Catton C. ⁸ , Logue J. ⁹ , Payne H. ¹⁰ , Saad F. ¹¹ , Brasso K. ⁵ , Lindberg H. ¹² , Zarkar A. ¹³ , Raman R. ¹⁴ , Roder M.A. ⁵ , Heath C. ¹⁵ , Parulekar W. ¹⁶ , Parmar M. ³ , Sydes M. ³
  
  Institutes: ¹Royal Marsden NHS Foundation Trust, Dept. of Oncology, Sutton, United Kingdom, ²The Christie and Salford Royal Hospitals, Department of Surgery, Manchester, United Kingdom, ³MRC Clinical Trials Unit at UCL, Dept. of Clinical Trials, London, United Kingdom, ⁴Cardiff School of Medicine, Division of Cancer and Genetics, Cardiff, United Kingdom, ⁵Rigshospitalet, University Hospital Copenhagen, Dept. of Oncology, Copenhagen, Denmark, ⁶St James University Hospital, Dept. of Urology, Leeds, Denmark, ⁷Bristol Urological Institute, North Bristol Hospitals, Dept. of Urology, Bristol, United Kingdom, ⁸Princess Margaret Hospital/University Health Network, Dept. of Radiation Oncology, Toronto, Canada, ⁹The Christie Hospital, Dept. of Oncology, Manchester, United Kingdom, ¹⁰University College London Hospitals, Dept. of Oncology, London, United Kingdom, ¹¹Hospital St. Luc du CHUM, Dept. of Urology, Montreal, Canada, ¹²Herlev Hospital, Dept. of Oncology, Herlev, Denmark, ¹³University Hospital Birmingham, Dept. of Oncology, Birmingham, United Kingdom, ¹⁴Kent Oncology Centre, Dept. of Clinical Oncology, Canterbury, United Kingdom, ¹⁵University Hospital Southampton, Dept. of Clinical Oncology, Southampton, United Kingdom, ¹⁶Queen's University, Canadian Cancer Trials Group, Dept. of Oncology, Ontario, Canada
  
  Webcast
  
  P163
  
  Intraprostatic injection of Liproca® Depot (2-hydroxy flutamide) in patient with localised prostate cancer
  
  By: Klotz L.H. ¹ , Axén N. ² , Grudén S. ³ , Gauffin C. ⁴ , Giddens J. ⁵ , Incze P. ⁶ , Jansz K. ⁷ , Jievaltas M. ⁸ , Rendon R. ⁹ , Ulys A. ¹⁰ , Bjartell A. ¹¹ , Tammela T. ¹²
  
  Institutes: ¹University of Toronto, Dept. of Urology, Toronto, Canada, ²LIDDS AB, Dept. of Biomaterials and Devices, Uppsala, Sweden, ³LIDDS AB, Dept. of Pharmaceutical R&D, Uppsala, Sweden, ⁴LIDDS AB, Dept. of Clinical Development, Uppsala, Sweden, ⁵Jonathan Giddens Medicine Professional Corp, Dept. of Urology, Brampton, Canada, ⁶Oakville Trafalgar Memorial Hospital, Dept. of Urological Surgery, Oakville, Canada, ⁷Burlington Professional Centre, Dept. of Urology, Burlington, Canada, ⁸Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Dept. of Urology, Kaunas, Lithuania, ⁹Centre of Applied Urology Research, Dept. of Urology, Halifax, Canada, ¹⁰National Cancer Institute, Dept. of Oncology, Vilnius, Lithuania, ¹¹Skåne University Hospital, Dept. of Translational Medicine, Malmö, Sweden, ¹²Tampere University Hospital, Dept. of Surgery, Tampere, Finland
  
  Webcast
13. Plenary Session 11 - False positives findings in uro-oncology and their clinical impact
  
  False positives findings in uro-oncology and their clinical impact Plenary Session 11
  
  11:25 - 12:05
  False positives findings in uro-oncology and their clinical impact
  
  Plenary Session 11
  
  Sat 16 November
  11:25 - 12:05
  
  Location:
  
  Auditorium
  
  Chairs:
  
  I.J. De Jong, Groningen (NL)
  H. Thoeny, Bern (CH)
  A. Bossi, Villejuif (FR)
  
  11:25 - 11:35
  
  Imaging: PSMA PET
  
  D. Deandreis, ()
  
  Webcast
  
  11:35 - 11:45
  
  Imaging: MRI of the prostate
  
  R. Renard-Penna, Paris (FR)
  
  Webcast
  
  11:45 - 11:55
  
  False positive results in pathology
  
  F. Algaba, Barcelona (ES)
  
  Webcast
  
  11:55 - 12:05
  
  Discussion
14. Closing remarks
  
  Closing remarks
  
  11:40 - 11:50
  Closing remarks
  
  Sun 17 November
  11:40 - 11:50
  
  Location:
  
  Auditorium
  
  Chairs:
  
  L. Albiges, Villejuif (FR)
  P. Hoskin, Northwood (GB)
  H.P.A.M. Van Poppel, Leuven (BE)
15. Plenary Session 03 - Highlights in GU cancers
  
  Highlights in GU cancers Plenary Session 03
  
  12:00 - 12:40
  Highlights in GU cancers
  
  Plenary Session 03
  
  Fri 15 November
  12:00 - 12:40
  
  Location:
  
  Auditorium
  
  Chairs:
  
  J. Walz, Marseille (FR)
  R. Oyen, Leuven (BE)
  
  12:00 - 12:10
  
  Results of the APCCC meeting
  
  N. Mottet, Saint-Étienne (FR)
  
  Webcast
  
  12:10 - 12:20
  
  Highlights from ESUI
  
  G. Salomon, Hamburg (DE)
  
  Webcast
  
  12:20 - 12:30
  
  The EAU Research Foundation: Trials in progress
  
  A.S. Bjartell, Malmö (SE)
  
  Webcast
  
  12:30 - 12:40
  
  Highlights from PRIAS
  
  M.J. Roobol, Rotterdam (NL)
  
  Webcast
16. Plenary Session 12 - Oral presentation of the 6 best abstracts
  
  Oral presentation of the 6 best abstracts Plenary Session 12
  
  12:00 - 12:40
  Oral presentation of the 6 best abstracts
  
  Plenary Session 12
  
  Sat 16 November
  12:00 - 12:40
  
  Location:
  
  Auditorium
  
  Chairs:
  
  A. Bamias, Athens (GR)
  C. Salembier, Brussels (BE)
  A. Briganti, Milan (IT)
  
  O2
  
  Proteome-based classification of non-muscle invasive bladder cancer
  
  By: Fragkoulis C. ¹ , Stroggilos R. ² , Latosinska A. ³ , Makridakis M. ² , Lygirou V. ² , Mavrogeorgis E. ⁴ , Drekolias D. ⁵ , Frantzi M. ³ , Mullen W. ⁶ , Stasinopoulos K. ¹ , Papadopoulos G. ¹ , Stathouros G. ¹ , Lazaris A. ⁵ , Makrythanasis P. ² , Ntoumas K. ¹ , Mischak H. ³ , Zoidakis J. ² , Vlahou A. ²
  
  Institutes: ¹General Hospital of Athens, Dept. of Urology, Athens, Greece, ²Biomedical Research Foundation of the Academy of Athens, Dept. of Biotechnology, Athens, Greece, ³Mosaiques Diagnostics GmbH, Mosaiques Diagnostics, Hannover, Germany, ⁴Agricultural University of Athens, Dept. of Biotechnology, Athens, Greece, ⁵Medical School of Athens, Dept. of Pathology, Athens, Greece, ⁶British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, , Cardiovascular Research Centre, Glaskow, United Kingdom
  
  O3
  
  The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines
  
  By: Jansen B.H.E. ¹ , Van Leeuwen P. ² , Wondergem M. ³ , Van Der Sluis T. ¹ , Nieuwenhuijzen J. ¹ , Knol R. ³ , Van Moorselaar J. ¹ , Van Der Poel H. ² , Oprea-Lager D. ⁴ , Vis A. ¹
  
  Institutes: ¹Vrije Universiteit, Dept. of Urology, Amsterdam, The Netherlands, ²Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ³Noordwest Groep, Dept. of Nuclear Medicine, Alkmaar, The Netherlands, ⁴Vrije Universiteit, Dept. of Radiology and Nuclear Medicine, Amsterdam, The Netherlands
  
  Webcast
  
  O4
  
  Micro-ultrasound versus multiparametric MRI in the detection of prostate cancer: Results from a prospective single center trial
  
  By: Maffei D. ¹ , Paciotti M. ¹ , Lazzeri M. ¹ , Frego N. ¹ , Fasulo V. ¹ , Diana P. ¹ , Regis F. ¹ , Elefante G.M. ² , Colombo P. ² , Saita A.R. ¹ , Hurle R. ¹ , Casale P. ¹ , Buffi N.M. ³ , Guazzoni G.F. ³ , Lughezzani G. ³
  
  Institutes: ¹Humanitas Clinical and Research Center, Dept. of Urology, Rozzano, Italy, ²Humanitas Clinical and Research Center, Dept. of Anatomopathology, Rozzano, Italy, ³Humanitas University, Dept. of Urology, Rozzano, Italy
  
  Webcast
  
  O5
  
  Safety of abiraterone and enzalutamide in prostate cancer patients treated with anticoagulants
  
  By: Goena Vives M.C. ¹ , Rilo I. ² , Garcia R. ¹ , Mañas L. ¹ , Beramendi J.R. ² , Quintas L. ¹
  
  Institutes: ¹Mendaro Hospital, Dept. of Cardiology, Mendaro, Spain, ²Donostia University Hospital, Dept. of Cardiology, San Sebastian, Spain
  
  Webcast
  
  O6
  
  Patient-reported outcomes (PROs) from TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic Castration-Sensitive Prostate Cancer (mCSPC)
  
  By: Agarwal N. ¹ , Mcquarrie K. ² , Bjartell A. ³ , Chowdhury S. ⁴ , Pereira De Santana Gomes A.J. ⁵ , Chung B.H. ⁶ , Özgüroğlu M. ⁷ , Juárez Soto Á. ⁸ , Merseburger A.S. ⁹ , Uemura H. ¹⁰ , Ye D-W. ¹¹ , Given R. ¹² , Miladinovic B. ¹³ , Dearden L. ¹⁴ , Deprince K. ¹⁵ , Naini V. ¹⁶ , Lopez-Gitlitz A. ¹⁷ , Chi K.N. ¹⁸
  
  Institutes: ¹University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, ²Janssen Research & Development, Strategic Market Access, Horsham, United States of America, ³Skåne University Hospital, Lund University, Malmo, Sweden, ⁴Guy's, King's, and St Thomas' Hopitals and Sarah Cannon Research Institute, Dept. of Medical Oncology, London, United Kingdom, ⁵Liga Norte Riograndense Contra O Cancer, Dept. of Oncology, Natal, Brazil, ⁶Yonsei University College of Medicine and Gangnam Severance Hospital, Dept. of Urology, Seoul, South Korea, ⁷Istanbul University-Cerrahpaşa, Dept. of Oncology, Istanbul, Turkey, ⁸Hospital Universitario de Jerez de la Frontera, Dept. of Urology, Cadiz, Spain, ⁹University Hospital Schleswig-Holstein, Dept. of Urology, Lübeck, Germany, ¹⁰Kindai University Faculty of Medicine, Dept. of Urology, Osaka, Japan, ¹¹Fudan University, Shanghai Cancer Center, Dept. of Urology, Shanghai, China, ¹²Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, ¹³Janssen Research & Development, Clinical Biostats, San Diego, United States of America, ¹⁴Janssen Global Services, Global Market Access, Raritan, United States of America, ¹⁵Janssen Research & Development, Dept. of Oncology, Beerse, Belgium, ¹⁶Janssen Research & Development, Dept. of Oncology, San Diego, United States of America, ¹⁷Janssen Research & Development, Dept. of Oncology, Los Angeles, United States of America, ¹⁸BC Cancer, Dept. of Medicine, Vancouver, Canada
  
  Webcast
17. Industry Session BAYER - Recent advances in sequencing strategies for advanced prostate cancer
  
  Recent advances in sequencing strategies for advanced prostate cancer Industry Session BAYER
  
  13:00 - 14:00
  Recent advances in sequencing strategies for advanced prostate cancer
  
  Industry Session BAYER
  
  Fri 15 November
  13:00 - 14:00
  
  Location:
  
  Auditorium
  
  13:00 - 13:10
  
  Welcome and introduction
  
  G. Kramer, Vienna (AT)
  
  13:10 - 13:25
  
  Beyond ADT: treatment sequencing in non-metastatic castration-resistant disease
  
  G. Kramer, Vienna (AT)
  
  13:25 - 13:35
  
  On the move: identifying metastatic disease in practice
  
  P. Ost, Ghent (BE)
  
  13:35 - 13:50
  
  Taking the next step: treatment sequencing in metastatic castration-resistant prostate cancer
  
  P. Ost, Ghent (BE)
  
  13:50 - 14:00
  
  Q&A
  
  G. Kramer, Vienna (AT)
18. Industry Session SANOFI - Optimizing survival in metastatic prostate cancer
  
  Optimizing survival in metastatic prostate cancer Industry Session SANOFI
  
  13:00 - 14:00
  Optimizing survival in metastatic prostate cancer
  
  Industry Session SANOFI
  
  Sat 16 November
  13:00 - 14:00
  
  Location:
  
  Auditorium
  
  13:00 - 13:05
  
  Welcome and introduction
  
  N. Mottet, Saint-Étienne (FR)
  
  13:05 - 13:20
  
  Metastatic prostate cancer in 2019: learnings from randomized clinical trials
  
  G. Kramer, Vienna (AT)
  
  13:20 - 13:35
  
  Managing metastatic disease in daily practice
  
  A. Birtle, Preston (GB)
  
  13:35 - 13:50
  
  Metastatic prostate cancer in 2019: EAU guidelines
  
  N. Mottet, Saint-Étienne (FR)
  
  13:50 - 14:00
  
  Discussion and closing remarks
  
  N. Mottet, Saint-Étienne (FR)
19. Novelties in non-muscle invasive bladder cancer
  
  Novelties in non-muscle invasive bladder cancer
  
  14:00 - 15:15
  Novelties in non-muscle invasive bladder cancer
  
  Fri 15 November
  14:00 - 15:15
  
  Location:
  
  Auditorium
  
  Chairs:
  
  A. Necchi, Milan (IT)
  M. Rouprêt, Paris (FR)
  G. Mikuz, Innsbruck (AT)
  
  14:00 - 14:15
  
  VI-RADS for the management of non-muscle-invasive bladder cancer
  
  V. Panebianco, Rome (IT)
  
  Webcast
  
  14:15 - 14:30
  
  Intravesical alternatives for non-muscle-invasive bladder cancer treatment
  
  A.M. Kamat, Houston (US)
  
  Webcast
  
  14:30 - 14:40
  
  Novel biomarkers - urinary markers for in non-muscle-invasive bladder cancer
  
  L. Dyrskjøt, Aarhus (DK)
  
  Webcast
  
  14:40 - 14:55
  
  Morphological changes after therapy
  
  A. Lopez-Beltran, Lisbon (PT)
  
  Webcast
  
  14:55 - 15:15
  
  Discussion
20. Plenary Session 13 - Small renal masses in patients with different comorbidity profiles
  
  Small renal masses in patients with different comorbidity profiles Plenary Session 13
  
  14:00 - 16:00
  Small renal masses in patients with different comorbidity profiles
  
  Plenary Session 13
  
  Sat 16 November
  14:00 - 16:00
  
  Location:
  
  Auditorium
  
  Chairs:
  
  H.P.A.M. Van Poppel, Leuven (BE)
  K. Junker, Homburg (DE)
  B. Vanneste, Maastricht (NL)
  
  14:00 - 14:10
  
  Case presentation (including voting, 2 cases)
  
  A. Larcher, Milan (IT)
  
  Webcast
  
  14:10 - 14:25
  
  How to do active surveillance?
  
  A. Volpe, Novara (IT)
  
  Webcast
  
  14:25 - 14:40
  
  Surgery, focal: What to do when?
  
  A. Finelli, Toronto (CA)
  
  Webcast
  
  14:40 - 14:55
  
  Stereotactic body radiotherapy (SBRT) for kidney cancer
  
  B. Vanneste, Maastricht (NL)
  
  14:55 - 15:10
  
  Contrast-enhanced ultrasound
  
  J.M. Correas, Paris (FR)
  
  Webcast
  
  15:10 - 15:25
  
  Histological and molecular differentiation of small renal masses
  
  K. Junker, Homburg (DE)
  
  Webcast
  
  15:25 - 16:00
  
  Discussion and conclusion on cases (including voting)
  
  Webcast
21. Nightmare session: It could happen to you…
  
  Nightmare session: It could happen to you…
  
  15:15 - 15:45
  Nightmare session: It could happen to you…
  
  Fri 15 November
  15:15 - 15:45
  
  Location:
  
  Auditorium
  
  Chairs:
  
  C. Cozzarini, Milan (IT)
  A. Stenzl, Tübingen (DE)
  
  15:15 - 15:25
  
  Surgery
  
  R. Sanchez-Salas, Paris (FR)
  
  Webcast
  
  15:25 - 15:30
  
  Discussion
  
  15:30 - 15:40
  
  Radiation therapy
  
  T. Wiegel, Ulm (DE)
  
  Webcast
  
  15:40 - 15:45
  
  Discussion
22. Challenge the expert
  
  • Complete response after neoadjuvant chemotherapy or immunotherapy
  • Histological variants in non-muscle invasive bladder cancer
  • Upper tract recurrence after cystectomy
  
  Challenge the expert
  
  16:15 - 17:30
  Challenge the expert
  
  Fri 15 November
  16:15 - 17:30
  
  Location:
  
  Auditorium
  
  Discussants:
  
  M. De Santis, Berlin (DE)
  S. Shariat, Vienna (AT)
  V. Fonteyne, Ghent (BE)
  R. Renard-Penna, Paris (FR)
  M. Fiorentino, Bologna (IT)
  
  16:15 - 16:40
  
  Multidisciplinary case discussion Complete response after neoadjuvant chemotherapy or immunotherapy
  
  Y. Loriot, Villejuif (FR)
  
  Webcast
  
  16:40 - 17:05
  
  Multidisciplinary case discussion Histological variants in non-muscle invasive bladder cancer
  
  M. Moschini, Luzern (CH)
  
  Webcast
  
  17:05 - 17:30
  
  Multidisciplinary case discussion Upper tract recurrence after cystectomy
  
  B.M. Kiss, Bern (CH)
  
  Webcast
23. Plenary Session 14 - Combined treatment with immunotherapy
  
  Combined treatment with immunotherapy Plenary Session 14
  
  16:30 - 17:30
  Combined treatment with immunotherapy
  
  Plenary Session 14
  
  Sat 16 November
  16:30 - 17:30
  
  Location:
  
  Auditorium
  
  Chairs:
  
  B. De Bari, Besancon (FR)
  A. Bex, London (GB)
  M. Schmidinger, Vienna (AT)
  
  16:30 - 16:45
  
  Immunotherapy and radiotherapy
  
  A.R. Filippi, Pavia (IT)
  
  16:45 - 17:00
  
  Immunotherapy and systemic treatment
  
  T. Powles, London (GB)
  
  17:00 - 17:15
  
  Peri-operative immunotherapy in 2019
  
  J. Bedke, Tübingen (DE)
  
  Webcast
  
  17:15 - 17:30
  
  Discussion
24. Industry Session JANSSEN - New data in advanced prostate cancer: What does it mean for your practice?
  
  New data in advanced prostate cancer: What does it mean for your practice? Industry Session JANSSEN
  
  17:45 - 18:45
  New data in advanced prostate cancer: What does it mean for your practice?
  
  Industry Session JANSSEN
  
  Fri 15 November
  17:45 - 18:45
  
  Location:
  
  Auditorium
  
  17:45 - 17:50
  
  Welcome and introduction
  
  A.S. Merseburger, Lübeck (DE)
  
  17:50 - 18:20
  
  New data in mHSPC
  M. De Santis, Berlin (DE)
  A.S. Merseburger, Lübeck (DE)
  
  18:20 - 18:40
  
  Caring for patients with nmCRPC
  M. De Santis, Berlin (DE)
  S. Chowdhury, London (GB)
  
  18:40 - 18:45
  
  Key learnings and pressing questions
  
  S. Chowdhury, London (GB)
Hall G2
1. YAU Meeting - YAU Autumn Meeting
  
  YAU Autumn Meeting YAU Meeting
  
  10:00 - 12:00
  YAU Autumn Meeting
  
  YAU Meeting
  
  Thu 14 November
  10:00 - 12:00
  
  Location:
  
  Hall G2
  
  Moderator:
  
  M.S. Silay, Istanbul (TR)
  
  Discussant:
  
  To be confirmed
  
  10:00 - 10:10
  
  YAU Overview
  
  M.S. Silay, Istanbul (TR)
  
  Webcast
  
  10:10 - 11:00
  
  YAU Working parties reports
  
  10:10 - 10:15
  
  Renal Cell Carcinoma
  
  U. Capitanio, Milan (IT)
  
  10:15 - 10:20
  
  Prostate Cancer
  
  G. Gandaglia, Milan (IT)
  
  10:20 - 10:25
  
  Urothelial
  
  E. Xylinas, Paris (FR)
  
  10:25 - 10:30
  
  Endourology & Urolithiasis
  
  P. Kallidonis, Patras (GR)
  
  10:30 - 10:35
  
  Pediatric Urology
  
  B. Haid, Linz (AT)
  
  10:35 - 10:40
  
  Men’s Health
  
  G.I. Russo, Catania (IT)
  
  10:40 - 10:45
  
  Functional Urology
  
  T.A.T. Marcelissen, Maastricht (NL)
  
  10:45 - 10:50
  
  ERUS-Robotic
  
  G. De Naeyer, Aalst (BE)
  
  10:50 - 10:55
  
  Urotechnology
  
  D. Veneziano, Reggio Calabria (IT)
  
  10:55 - 11:00
  
  Reconstructive
  
  L.A. Kluth, Frankfurt a.M. (DE)
  
  11:00 - 11:15
  
  Establishing a professional career at a European level: Motivational talk by a Crystal Matula Award Winner
  
  S. Shariat, Vienna (AT)
  
  Webcast
  
  11:15 - 11:25
  
  Young Urologist Leadership Course
  
  H. Rijksen, Maarsbergen (NL)
  
  Webcast
2. EAU Section Uro-Pathology (ESUP) Symposium, organized with EAU Section Urological Research (ESUR) and European Society of Pathology Uropathology Working Group - Current applications and future perspectives of liquid biopsies in Uro-Oncology
  
  Current applications and future perspectives of liquid biopsies in Uro-Oncology EAU Section Uro-Pathology (ESUP) Symposium, organized with EAU Section Urological Research (ESUR) and European Society of Pathology Uropathology Working Group
  
  13:30 - 16:30
  Current applications and future perspectives of liquid biopsies in Uro-Oncology
  
  EAU Section Uro-Pathology (ESUP) Symposium, organized with EAU Section Urological Research (ESUR) and European Society of Pathology Uropathology Working Group
  
  Thu 14 November
  13:30 - 16:30
  
  Location:
  
  Hall G2
  
  Chairs:
  
  R. Montironi, Ancona (IT)
  A. Lopez-Beltran, Lisbon (PT)
  K. Junker, Homburg (DE)
  H.P.A.M. Van Poppel, Leuven (BE)
  
  13:30 - 13:35
  
  Introduction
  
  H.P.A.M. Van Poppel, Leuven (BE)
  
  13:35 - 14:00
  
  Current applications of liquid biopsies: What we need to know before starting using them?
  
  M. Fiorentino, Bologna (IT)
  
  Webcast
  
  14:00 - 14:25
  
  Molecular characterization and diagnostic criteria of kidney cancer with emphasis on liquid biopsies
  
  K. Junker, Homburg (DE)
  
  Webcast
  
  14:25 - 14:50
  
  An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies
  
  M. Eckstein, Erlangen (DE)
  
  Webcast
  
  14:50 - 15:15
  
  Liquid biopsies and bladder cancer
  
  T. Gevaert, Leuven (BE)
  
  Webcast
  
  15:15 - 15:40
  
  Current bladder cancer biomarkers with emphasis on urine biomarkers
  
  A. Lopez-Beltran, Lisbon (PT)
  
  Webcast
  
  15:40 - 16:05
  
  Future perspectives of liquid biopsies in Uro-Oncology
  
  S. Riethdorf, Hamburg (DE)
  
  Webcast
  
  16:05 - 16:30
  
  Discussion and conclusions
  
  R. Montironi, Ancona (IT)
  
  Webcast
3. Uropathology Course - Morphologic and molecular classification of bladder cancer
  
  Morphologic and molecular classification of bladder cancer Uropathology Course
  
  16:45 - 17:45
  Morphologic and molecular classification of bladder cancer
  
  Uropathology Course
  
  Thu 14 November
  16:45 - 17:45
  
  Location:
  
  Hall G2
  
  Chairs:
  
  R. Montironi, Ancona (IT)
  A. Lopez-Beltran, Lisbon (PT)
  D. Ertoy Baydar, Istanbul (TR)
  
  Learning objectives
  
  The joint histological evaluation of specimens of bladder and prostate cancer by the clinician and uropathologist can produce much more clinical and prognostic information than that contained in the final histopathology report. Both the clinician and uropathologist can benefit from such an approach. The former will more clearly understand and explain the preoperative features of the cancer, the intraoperative findings, and postoperative follow-up of the patient. The experience acquired would help improve him/her diagnostic and prognostication capabilities and surgical skill. The uropathologist will learn the great clinical significance of his/her daily routine. The course will be based on the projection and discussion of virtual slides.
Hall K1
1. ESU Course 01 - Oligometastases in genito urinary cancers
  
  Oligometastases in genito urinary cancers ESU Course 01
  
  09:00 - 12:00
  Oligometastases in genito urinary cancers
  
  ESU Course 01
  
  Thu 14 November
  09:00 - 12:00
  
  Location:
  
  Hall K1
  
  Chair:
  
  T. Maurer, Hamburg (DE)
  
  09:00 - 09:05
  
  European School of Urology: A unique possibility for urological education
  
  P.J. Van Leeuwen, Badhoevedorp (NL)
  
  Webcast
  
  09:05 - 09:10
  
  Introduction and aims
  
  Webcast
  
  09:10 - 09:40
  
  Definitions and biology of oligometastases
  
  P.J. Van Leeuwen, Badhoevedorp (NL)
  
  Webcast
  
  09:40 - 10:10
  
  Role of imaging modalities
  
  T. Maurer, Hamburg (DE)
  
  Webcast
  
  10:10 - 10:30
  
  Break
  
  10:30 - 11:00
  
  Radiotherapeutic management of oligometastases in prostate cancer
  
  G. De Meerleer, Leuven (BE)
  
  Webcast
  
  11:00 - 11:30
  
  Salvage surgical treatment of nodal metastases
  
  T. Maurer, Hamburg (DE)
  
  Webcast
  
  11:30 - 11:55
  
  Role of systemic therapy in oligometastasized disease
  
  P.J. Van Leeuwen, Badhoevedorp (NL)
  
  Webcast
  
  11:55 - 12:00
  
  Take home messages and close
2. Industry Workshop FERRING - How do we maximise our window of opportunity to treat patients with NMIBC resistant to standard treatment?
  
  How do we maximise our window of opportunity to treat patients with NMIBC resistant to standard treatment? Industry Workshop FERRING
  
  12:30 - 13:30
  How do we maximise our window of opportunity to treat patients with NMIBC resistant to standard treatment?
  
  Industry Workshop FERRING
  
  Thu 14 November
  12:30 - 13:30
  
  Location:
  
  Hall K1
  
  12:30 - 12:35
  
  Welcome
  
  S. Shariat, Vienna (AT)
  
  12:35 - 12:40
  
  Introduction
  
  M. Rouprêt, Paris (FR)
  
  12:40 - 13:10
  
  Case-based discussion in high-risk NMIBC: Potential for new approaches
  
  A. Necchi, Milan (IT)
  
  13:10 - 13:20
  
  Future outlook in NMIBC: Multiple perspectives
  
  A. Necchi, Milan (IT)
  
  13:20 - 13:30
  
  Audience Q&A: Talking points from other clinics
  
  A. Necchi, Milan (IT)
3. ESU Course 02 - Immunotherapy for urological tumours
  
  Immunotherapy for urological tumours ESU Course 02
  
  14:00 - 17:00
  Immunotherapy for urological tumours
  
  ESU Course 02
  
  Thu 14 November
  14:00 - 17:00
  
  Location:
  
  Hall K1
  
  Chair:
  
  R.J.A. Van Moorselaar, Amsterdam (NL)
  
  14:00 - 14:05
  
  European School of Urology: A unique possibility for urological education
  
  R.J.A. Van Moorselaar, Amsterdam (NL)
  
  Webcast
  
  14:05 - 14:25
  
  Update and current knowledge of immunotherapy in prostate cancer
  
  R.J.A. Van Moorselaar, Amsterdam (NL)
  
  Webcast
  
  14:25 - 14:55
  
  Immunotherapy for urological tumours: Clinical cases in prostate cancer
  
  R.J.A. Van Moorselaar, Amsterdam (NL)
  
  Webcast
  
  14:55 - 15:15
  
  Break
  
  15:15 - 15:35
  
  Update and current knowledge of immunotherapy in renal cancer
  
  M-O. Grimm, Jena (DE)
  
  Webcast
  
  15:35 - 16:05
  
  Immunotherapy for urological tumours: Clinical cases in renal cancer
  
  M-O. Grimm, Jena (DE)
  
  Webcast
  
  16:05 - 16:25
  
  Update and current knowledge of immunotherapy in bladder cancer
  
  R.J. Jones, Glasgow (GB)
  
  Webcast
  
  16:25 - 16:55
  
  Immunotherapy for urological tumours: Clinical cases in bladder cancer
  
  R.J. Jones, Glasgow (GB)
  
  Webcast
  
  16:55 - 17:00
  
  Closing remarks
4. ESU 2 barcodes - ESU barcode 2
  
  ESU barcode 2 ESU 2 barcodes
  
  17:00 - 18:00
  ESU barcode 2
  
  ESU 2 barcodes
  
  Thu 14 November
  17:00 - 18:00
  
  Location:
  
  Hall K1
Room 0.12
1. FALCON - Pelvic nodal irradiation: Any news in the the new era of imaging?
  
  Pelvic nodal irradiation: Any news in the the new era of imaging? FALCON
  
  14:00 - 16:00
  Pelvic nodal irradiation: Any news in the the new era of imaging?
  
  FALCON
  
  Sat 16 November
  14:00 - 16:00
  
  Location:
  
  Room 0.12
  
  Chairs:
  
  B. De Bari, Besancon (FR)
  F. Giammarile, ()
  F. Alongi, Verona (IT)
Hall G1
1. ESUI Meeting - 8th Meeting of the EAU Section of Urological Imaging
  
  8th Meeting of the EAU Section of Urological Imaging ESUI Meeting
  
  08:30 - 18:00
  8th Meeting of the EAU Section of Urological Imaging
  
  ESUI Meeting
  
  Thu 14 November
  08:30 - 18:00
  
  Location:
  
  Hall G1
Foyer
1. Coffee break and poster viewing
  
  Coffee break and poster viewing
  
  10:00 - 10:30
  Coffee break and poster viewing
  
  Sat 16 November
  10:00 - 10:30
  
  Location:
  
  Foyer
2. Coffee break and poster viewing
  
  Coffee break and poster viewing
  
  10:30 - 11:00
  Coffee break and poster viewing
  
  Fri 15 November
  10:30 - 11:00
  
  Location:
  
  Foyer
3. Lunch break and poster viewing
  
  Lunch break and poster viewing
  
  12:40 - 14:00
  Lunch break and poster viewing
  
  Fri 15 November
  12:40 - 14:00
  
  Location:
  
  Foyer
4. Lunch break and poster viewing
  
  Lunch break and poster viewing
  
  12:40 - 14:00
  Lunch break and poster viewing
  
  Sat 16 November
  12:40 - 14:00
  
  Location:
  
  Foyer
5. Coffee break and poster viewing
  
  Coffee break and poster viewing
  
  15:45 - 16:15
  Coffee break and poster viewing
  
  Fri 15 November
  15:45 - 16:15
  
  Location:
  
  Foyer
6. Coffee break and poster viewing
  
  Coffee break and poster viewing
  
  16:00 - 16:30
  Coffee break and poster viewing
  
  Sat 16 November
  16:00 - 16:30
  
  Location:
  
  Foyer
Room 0.94 - 0.95
1. HOT MRI reading - Course 1 - ESU/ESUI Hands-on Training Course in Prostate MRI reading for urologist
  
  Course 1 - ESU/ESUI Hands-on Training Course in Prostate MRI reading for urologist HOT MRI reading
  
  09:30 - 13:00
  Course 1 - ESU/ESUI Hands-on Training Course in Prostate MRI reading for urologist
  
  HOT MRI reading
  
  Fri 15 November
  09:30 - 13:00
  
  Location:
  
  Room 0.94 - 0.95
  
  Chair:
  
  J. Walz, Marseille (FR)
  
  Tutors:
  
  F. Sanguedolce, Barcelona (ES)
  J.J. Futterer, Nijmegen (NL)
  G. Giannarini, Udine (IT)
  V. Panebianco, Rome (IT)
Room 0.96 - 0.97
1. HOT MRI Fusion 1 - Course 1 -ESU/ESUI Hands-on Training Course in MRI Fusion biopsy
  
  Course 1 -ESU/ESUI Hands-on Training Course in MRI Fusion biopsy HOT MRI Fusion 1
  
  10:00 - 12:00
  Course 1 -ESU/ESUI Hands-on Training Course in MRI Fusion biopsy
  
  HOT MRI Fusion 1
  
  Fri 15 November
  10:00 - 12:00
  
  Location:
  
  Room 0.96 - 0.97
  
  Chair:
  
  L. Budäus, Hamburg (DE)
  
  Tutors:
  
  J.P. Radtke, Essen (DE)
  E. Baco, Oslo (NO)
  S. Boxler, Bern (CH)
  A. Borkowetz, Dresden (DE)
  A. Maxeiner, Berlin (DE)
2. HOT MRI Fusion 2 - Course 2 - ESU/ESUI Hands-on Training Course in MRI Fusion biopsy
  
  Course 2 - ESU/ESUI Hands-on Training Course in MRI Fusion biopsy HOT MRI Fusion 2
  
  14:00 - 16:00
  Course 2 - ESU/ESUI Hands-on Training Course in MRI Fusion biopsy
  
  HOT MRI Fusion 2
  
  Fri 15 November
  14:00 - 16:00
  
  Location:
  
  Room 0.96 - 0.97
  
  Chair:
  
  L. Budäus, Hamburg (DE)
  
  Tutors:
  
  K. Gunzel, Berlin (DE)
  To be confirmed
  To be confirmed
  To be confirmed
  
  14:00 - 16:00
  
  Introduction to Hitachi
  
  A. Maxeiner, Berlin (DE)
Hall F2
1. PRIAS - PRIAS meeting
  
  PRIAS meeting PRIAS
  
  13:00 - 18:15
  PRIAS meeting
  
  PRIAS
  
  Thu 14 November
  13:00 - 18:15
  
  Location:
  
  Hall F2
  
  13:00 - 13:10
  
  Welcome and Introduction
  C.H. Bangma, Rotterdam (NL)
  M.J. Roobol, Rotterdam (NL)
  
  13:10 - 13:30
  
  Overview of PRIAS , status 2019
  
  H.B. Luiting, Rotterdam (NL)
  
  13:30 - 13:45
  
  PRIAS Japan
  
  M. Sugimoto, Kagawa (JP)
  
  13:45 - 14:00
  
  Diet /interventions in men on AS
  
  L.D.F. Venderbos, Rotterdam (NL)
  
  14:00 - 14:20
  
  Quality of Life in AS
  
  L. Bellardita, Milano (IT)
  
  14:20 - 14:40
  
  Coffee break
  
  14:40 - 15:00
  
  The role of genetics in AS
  
  G. Jenster, Rotterdam (NL)
  
  15:00 - 15:15
  
  PRIAS and the GDPR
  L.D.F. Venderbos, Rotterdam (NL)
  J. Helleman, Rotterdam (NL)
  
  15:15 - 15:35
  
  The new PRIAS website
  
  H.B. Luiting, Rotterdam (NL)
  
  15:35 - 15:50
  
  PIONEER and PRIAS
  
  M.J. Roobol, Rotterdam (NL)
  
  15:50 - 16:10
  
  Coffee break
  
  16:10 - 16:25
  
  Movember GAP-3: joining forces 2.0
  
  J. Helleman, Rotterdam (NL)
  
  16:25 - 17:00
  
  Different aspects of MRI in Active Surveillance; What can PRIAS and GAP-3 contribute?
  C. Moore, London (GB)
  F. Giganti, London (GB)
  
  17:00 - 18:00
  
  Future of PRIAS, sustainability, new projects
  
  A. Rannikko, Helsinki (FI)
  
  18:00 - 18:15
  
  Summary, the way forward, announcement of award winners
  C.H. Bangma, Rotterdam (NL)
  M.J. Roobol, Rotterdam (NL)
2. Industry Session EPGONLINE.ORG - Are you testing? DNA repair alterations in prostate cancer care and cascade testing in family members
  
  Are you testing? DNA repair alterations in prostate cancer care and cascade testing in family members Industry Session EPGONLINE.ORG
  
  17:45 - 18:45
  Are you testing? DNA repair alterations in prostate cancer care and cascade testing in family members
  
  Industry Session EPGONLINE.ORG
  
  Sat 16 November
  17:45 - 18:45
  
  Location:
  
  Hall F2
  
  17:45 - 17:50
  
  Welcome and introductions
  
  N. Shore, Myrtle Beach (US)
  
  17:50 - 18:00
  
  Patient diagnosis and mCRPC
  
  N. Shore, Myrtle Beach (US)
  
  18:00 - 18:15
  
  Clinical impact of DNA damage repair alterations in prostate cancer
  
  J. De Bono, Sutton (GB)
  
  18:15 - 18:30
  
  Molecular diagnostics for testing DNA damage repair alterations
  
  A. Wyatt, Vancouver (CA)
  
  18:30 - 18:45
  
  Faculty discussion and meeting close
  
  N. Shore, Myrtle Beach (US)

Foyer

Room 0.94 - 0.95

Auditorium

Room 0.96 - 0.97

Hall G1

Hall F2

Hall G2

Hall K1

Room 0.12

Auditorium

Hall G2

Hall K1

Room 0.12

Hall G1

Foyer

Room 0.94 - 0.95

Room 0.96 - 0.97

Hall F2